Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- PeptiDream, JCR to Collaborate to Discover Peptide-Drug Conjugates that Pass Through Blood-Brain Barrier
February 24, 2016
- Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
February 23, 2016
- Shionogi’s Naldemedine Yields Positive PIII Results for Opioid-Induced Constipation
February 23, 2016
- Fuso’s Voluntary Recall Escalated to Order-Based Recall
February 23, 2016
- Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
February 22, 2016
- Merck Serono Likely to Halt Serophene Sales in Japan, Notification Sent Out to Medical Societies
February 22, 2016
- Sanofi Suffers 6.6% Decline in Japan Revenues
February 22, 2016
- Fuso Voluntarily Recalls Maltose-Lactated Ringer’s Inj. and Replas Injection Due to Mislabeling
February 22, 2016
- Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
- Fujifilm Begins US PI Study for Cancer Drug FF-10502
February 19, 2016
- Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
- US Merck to Sell Daiichi Sankyo’s Lixiana in 13 European Countries
February 18, 2016
- JCR to Roll Out Cell Therapy Temcell on Feb. 24; Medipal to Be Exclusive Distributor
February 18, 2016
- Genzyme Japan to Be Merged into Sanofi in July
February 17, 2016
- Eisai, Sysmex Link Up in Next-Gen Diagnostic Reagents for Dementia
February 16, 2016
- Shionogi Joins Cambridge Therapeutic Consortium
February 16, 2016
- Asahi Kasei, Pfizer Wind Up Recomodulin Copromotion Scheme
February 16, 2016
- Otsuka’s Pharma Sales Down Nearly 15% in 2015
February 15, 2016
- Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
February 15, 2016
- Astellas Completes Acquisition of Ocata
February 15, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…